STOCK TITAN

Rhythm Pharmaceu - RYTM STOCK NEWS

Welcome to our dedicated page for Rhythm Pharmaceu news (Ticker: RYTM), a resource for investors and traders seeking the latest updates and insights on Rhythm Pharmaceu stock.

Rhythm Pharmaceuticals (RYTM) is a commercial-stage biopharmaceutical company pioneering precision medicines for rare neuroendocrine diseases, including genetic obesity disorders. This page aggregates all official announcements, press releases, and verified news coverage related to RYTM's therapeutic advancements and operational developments.

Investors and stakeholders will find timely updates on regulatory milestones, clinical trial outcomes, financial disclosures, and strategic partnerships. The curated collection prioritizes primary-source materials including FDA submissions, research publications, and executive communications to ensure informational accuracy.

Track RYTM's progress in developing MC4R pathway therapies like IMCIVREE® (setmelanotide), with updates spanning global approvals, research expansions, and market access initiatives. Content is organized chronologically to facilitate efficient monitoring of the company's progress in addressing rare genetic conditions.

Bookmark this page for direct access to Rhythm Pharmaceuticals' latest verified updates. For complete market analysis, combine these resources with broader sector research and regulatory filings.

Rhea-AI Summary

Rhythm Pharmaceuticals (Nasdaq: RYTM) announced that David Meeker, M.D., will participate in a fireside chat at the BofA Securities 2021 Virtual Health Care Conference on May 12, 2021, at 4:15 p.m. ET. A live audio webcast will be available on the company's investor relations website, with a replay accessible for 30 days following the event.

Rhythm focuses on treating rare genetic diseases of obesity and has FDA-approved IMCIVREE™ (setmelanotide) for chronic weight management in patients aged six and older with specific genetic deficiencies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.16%
Tags
conferences
-
Rhea-AI Summary

Rhythm Pharmaceuticals reported promising developments in Q1 2021, including the first U.S. commercial sales of IMCIVREE™ (setmelanotide), which occurred late in March. The company showcased significant weight loss results in clinical trials for individuals with rare genetic obesity disorders. Financially, Rhythm raised $172.5 million through a public offering and generated $35,000 in product revenues. The net income for the quarter was $43.8 million, reversing a loss from the previous year. The cash position improved to $404.8 million, providing ample funding to sustain operations into 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.81%
Tags
-
Rhea-AI Summary

Rhythm Pharmaceuticals (Nasdaq: RYTM) announced that David Meeker, M.D., will participate in a fireside chat at the 20th Annual Needham & Co. Virtual Healthcare Conference on April 14, 2021, at 11:45 a.m. ET. A live audio webcast will be accessible on the company’s website, with a replay available for 30 days after the event.

The company focuses on therapies for rare genetic diseases of obesity, featuring its FDA-approved precision medicine, IMCIVREE™ (setmelanotide), for chronic weight management in eligible patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.64%
Tags
conferences
Rhea-AI Summary

Rhythm Pharmaceuticals (Nasdaq: RYTM) announced notable results from Phase 2 and Phase 3 studies of setmelanotide, presented at ENDO 2021. Heterozygous (HET) obesity patients achieved a mean weight loss of 12.3% at nine months. Phase 3 data showed significant weight and hunger reduction in patients with Bardet-Biedl and Alström syndromes. Overall, the safety profile was consistent with prior findings, including common adverse events like skin hyperpigmentation and nausea. These results reinforce setmelanotide's potential in treating rare genetic obesity disorders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Rhythm Pharmaceuticals (Nasdaq: RYTM) announced three late-breaking abstracts accepted for presentation at the ENDO 2021 Annual Meeting, occurring virtually from March 20-23. Dr. Sadaf Farooqi will present clinical data from a Phase 2 study of setmelanotide for heterozygous obesity linked to POMC, PCSK1, or LEPR gene variants. Additional presentations will cover data from a Phase 3 trial in patients with Bardet-Biedl Syndrome and safety analyses from two Phase 3 trials. Rhythm continues to advance therapies for rare genetic obesity disorders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.48%
Tags
none
-
Rhea-AI Summary

Rhythm Pharmaceuticals (RYTM) has received FDA approval for IMCIVREE, the first treatment for chronic weight management in patients with obesity due to POMC, PCSK1, or LEPR deficiencies. The company reported positive topline data from a Phase 3 trial for Bardet-Biedl syndrome and is advancing a broad development program for setmelanotide, with multiple clinical studies slated for 2021. Financially, Rhythm has strengthened its position with $98.5M from a Rare Pediatric Disease PRV sale and $161.6M from a public offering, extending its cash runway through at least mid-2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.55%
Tags
Rhea-AI Summary

Rhythm Pharmaceuticals (Nasdaq: RYTM) announced participation of David Meeker, M.D., CEO, in the Cowen & Co. 41st Annual Health Care Conference on March 3, 2021. He will partake in a fireside chat at 2:40 p.m. ET and a panel discussion on "New Drug Launches" at 10:20 a.m. ET. A live audio webcast will be accessible on the company's Investor Relations website, with a replay available for 30 days. Rhythm focuses on therapies for rare genetic diseases of obesity and has FDA-approved IMCIVREE™ for chronic weight management in specific genetic conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
conferences
-
Rhea-AI Summary

Rhythm Pharmaceuticals (Nasdaq: RYTM) announced the closing of its public offering of 5,750,000 common shares at $30.00 each on February 9, 2021, raising approximately $172.5 million in gross proceeds. This included the full exercise of a 750,000-share underwriter option. The offering was facilitated by Morgan Stanley, BofA Securities, Cowen, and Stifel as joint managers and was conducted under a previously filed shelf registration. Rhythm focuses on therapies for rare genetic obesity diseases and has FDA-approved treatment IMCIVREE for specific genetic deficiencies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.72%
Tags
-
Rhea-AI Summary

Rhythm Pharmaceuticals (Nasdaq: RYTM) announced a public offering of 5,000,000 shares at $30.00 each, aiming to fund its efforts in treating rare genetic obesity diseases. Additionally, underwriters have a 30-day option for 750,000 more shares. The offering, structured under an SEC shelf registration filed in 2018, is set to conclude on February 9, 2021. Morgan Stanley, BofA Securities, Cowen, and Stifel are managing the offering. The company emphasizes that this announcement is not a sales offer and acknowledges potential risks, including market conditions and clinical trial outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.77%
Tags
Rhea-AI Summary

Rhythm Pharmaceuticals (Nasdaq: RYTM) announced a proposed public offering of $150 million of its common stock, with a potential additional $22.5 million if underwriters exercise their option. The offering is managed by Morgan Stanley, BofA Securities, Cowen, and Stifel, and is subject to market conditions. The shares will be offered under a shelf registration statement filed with the SEC. This move aims to bolster the company's capabilities to develop therapies for rare genetic obesity diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.97%
Tags
Rhythm Pharmaceu

Nasdaq:RYTM

RYTM Rankings

RYTM Stock Data

3.90B
56.86M
0.54%
107.82%
8.14%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON